Quantcast

Latest Beta blockers Stories

2009-06-30 10:47:00

Award Recognizes Entrepreneurial Excellence LAWRENCEVILLE, N.J., June 30 /PRNewswire/ -- Aton Pharma, Inc. announced today that its Chief Executive Officer, Michael G. Wells, has received the Ernst & Young Entrepreneur Of The Year(R) 2009 Award in the emerging companies category in New Jersey. According to Ernst & Young LLP, the award recognizes outstanding entrepreneurs who are building and leading dynamic, growing businesses. Mr. Wells was selected by an independent panel of...

2009-05-18 08:00:00

WILMINGTON, Del., May 18 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that all wholesale ordering restrictions in place for TOPROL-XL(R) (metoprolol succinate) extended release tablets have been removed and that supply levels of TOPROL-XL are approaching near usual levels at all points in the distribution chain. AstraZeneca has been diligently working to help ensure adequate market supply of TOPROL-XL and the authorized generic metoprolol succinate following published...

2009-02-25 08:00:00

LAWRENCEVILLE, N.J., Feb. 25 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has acquired the U.S. marketing rights to the TIMOPTIC(R) product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle...

2009-01-27 09:48:34

Multi-institutional study supports controversial theory, reveals genetic key Just when the Food and Drug Administration is reconsidering the use of stimulants to treat asthma, a new research study offers further evidence to support a University of Houston professor's theory that an opposite approach to asthma treatment may be in order. Richard A. Bond, professor of pharmacology at the University of Houston College of Pharmacy (UHCOP), has been investigating whether beta-2 adrenoreceptor...

2008-10-30 03:00:27

Hi-Tech Pharmacal, a specialty pharmaceutical company, has announced that the FDA granted final approval to the company's abbreviated new drug application for dorzolamide ophthalmic solution, 2%. Hi-Tech's dorzolamide ophthalmic solution is the generic for Merck's Trusopt ophthalmic solution 2%, indicated for elevated intraocular pressure in patients with ocular hypertension or open-angel glaucoma. Hi-Tech said that it plans to launch generic dorzolamide ophthalmic solution 2% immediately.

2008-09-15 12:00:35

Othera Pharmaceuticals, Inc., today announced that it has initiated dosing in a Phase I/II clinical trial to determine the safety and efficacy of topical OT-730 in patients with ocular hypertension and glaucoma. The study is a randomized, multi-center, investigator-masked, timolol- and placebo-controlled evaluation of the safety and efficacy of OT-730 in reducing the intraocular pressure in subjects with ocular hypertension or open-angle glaucoma. Subjects will be randomized to one of 0.75%...

2008-08-24 22:57:20

By Rupali Mukherjee NEW DELHI: If you are hypertensive and have been prescribed one of the widely used class of medicines called beta blockers-drugs like atenolol, inderal and metaprolol- you could be running an unacceptable risk of diabetes. Recent research in the UK indicates that these drugs could increase blood sugar in patients suffering from diabetes, and in some cases led to onset of the disease among patients of high blood pressure. The study, carried out at National Heart and...

2008-08-01 12:01:08

BROOMFIELD, Colo., Aug. 1 /PRNewswire/ -- ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, announced today that it has appointed James Carr, PharmD, as vice president of marketing. In this newly created position, Mr. Carr will define and execute marketing programs to support the company's lead product candidate, Gencaro(TM) (bucindolol hydrochloride), a pharmacologically unique beta-blocker and...

2008-08-01 06:00:46

Othera Pharmaceuticals has submitted an investigational new drug application to the FDA for OT-730, an oculoselective beta-blocker, as a potential treatment for glaucoma. A Phase I-II safety and efficacy trial is planned for completion by the end of 2008. This study is a randomized, multi-center, investigator-masked, timolol- and placebo-controlled, Phase I-II evaluation of the safety and efficacy of OT-730 ophthalmic solution in reducing the intraocular pressure in subjects with ocular...

2008-07-30 09:01:27

Othera Pharmaceuticals, Inc., announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for OT-730, an oculoselective beta-blocker, as a potential treatment for glaucoma. A Phase 1-2 safety and efficacy trial is planned for completion by the end of 2008. OT-730 is a novel, internally developed next generation topical beta-blocker designed to lower intra-ocular pressure (IOP), the leading risk factor for developing...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related